

AmoyDx® Pan Lung Cancer Fusion PCR Panel

Unleashing the Potential of RT-PCR: Detect 82 Fusions in 7 Genes with a Single Run



Actionable

Detects 82 RNA fusions in 7 biomarkers recommended by clinical practice guidelines for Non-Small Cell Lung Cancer (NSCLC)



Timely

From sample to report in just 3 hours: ARAS PCR software automates analysis and report generation, accelerating clinical decisions



Clinically proven

Thousands of real-world cases have confirmed its high sensitivity and specificity



Cost-effective

Reduces equipment, reagent, and labor costs by maintaining equivalent accuracy

Comprehensive Biomarker Coverage in Targeted Therapies

	Number of Variants	Targeted Therapies
ALK	21	Alectinib, Brigatinib, Crizotinib, Lorlatinib, Ceritinib
RET	16	Selpercatinib, Pralsetinib, Cabozantinib, Repotrectinib
ROS1	13	Crizotinib, Entrectinib, Lorlatinib, Ceritinib
NTRK1/2/3	31	Lorlatinib, Entrectinib
METex14 skipping	1	Tepotinib, Capmatinib, Gumarontinib, Crizotinib

Ordering Information

Catalog Number	8.01.0333
Instrument	QuantStudio5, LightCycler480 II, cobas z 480, Bio-Rad CFX96, SLAN-96S

E-mail: info@amoydx.com

Address: 2 Science Park Drive, Ascent #01-08, Singapore 118222

©2025 AmoyDx, All rights reserved.



F252001